Tetraxetan

Summary

Tetraxetan (CHEMBL1721515) is a phase-3 clinical-stage small-molecule chelator; indicated across 6 conditions including neuroendocrine neoplasm and acute lymphoblastic leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 3
• Chemistry: 404.42 Da · C16H28N4O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1721515
Name	Tetraxetan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	121841
ChEBI	CHEBI:61028
Molecular formula	C16H28N4O8
Molecular weight	404.42
InChIKey	WDLRUFUQRNWCPK-UHFFFAOYSA-N

SMILES: C1CN(CCN(CCN(CCN1CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O

IUPAC name: 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid

ChEBI definition: An azamacrocyle in which four nitrogen atoms at positions 1, 4, 7 and 10 of a twelve-membered ring are each substituted with a carboxymethyl group.

Pharmacological roles (ChEBI): chelator, copper chelator.

Also known as: DOT-A, DOTA, Dota acid, NSC-681107, Tetraxetan, SID56320897, SID518671, TETRAXETAN, GADOTERATE-MEGLUMINE, gadoterate-meglumine

Patent coverage: 11,504 distinct patent families (38,488 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Metallo-beta-lactamase type 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
C7C422	5.87	IC50	1340	nM	CHEMBL_ACT_29305800

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
acute lymphoblastic leukemia	1	MONDO:0004967	EFO:0000220
diffuse large B-cell lymphoma	1	MONDO:0018905	EFO:0000403
carcinoma	1	MONDO:0004993	EFO:0000313
lymphoma	1	MONDO:0005062	EFO:0000574
sarcoma	1	MONDO:0005089	EFO:0000691

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01101581	PHASE1/PHASE2	WITHDRAWN	Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
NCT01147393	PHASE1/PHASE2	TERMINATED	Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
NCT02844530	PHASE2	WITHDRAWN	Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).